Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis (RA-ILD): data from the INBUILD trial

Please find below an infographic on the data from the RA-ILD subgroup of the INBUILD trial.

Header - Navigation Icon

The INBUILD trial was supported by Boehringer Ingelheim International GmbH (BI). All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. The authors did not receive payment for development of this infographic or the manuscript on which it was based. Writing assistance was provided by Elizabeth Ng and Wendy Morris of Fleishman-Hillard, London, UK, which was contracted and funded by BI.